|Table of Contents|

Relationship between KRAS and BRAF gene mutations and clinicopathology and prognosis in colorectal cancer tissues

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 04
Page:
626-631
Research Field:
Publishing date:

Info

Title:
Relationship between KRAS and BRAF gene mutations and clinicopathology and prognosis in colorectal cancer tissues
Author(s):
CHEN Haixia; HE Yanan; WANG Weina; MA Xiaomei
Pathology Department,Affiliated Tumor Hospital of Xinjiang Medical University,Xinjiang Urumqi 830011,China.
Keywords:
colorectal cancer; KRAS; BRAF; gene mutation; clinicopathological features; prognosis
PACS:
R735.3+5；R735.3+7
DOI:
10.3969/j.issn.1672-4992.2021.04.017
Abstract:
Objective：To explore the relationship between KRAS and BRAF gene mutations and clinicopathology and prognosis in colorectal cancer(CRC).Methods:A retrospective analysis of 134 cases of colorectal cancer tissues were performed using the amplified block mutation system (ARMS) method.Results:The mutation rate of KRAS gene in 134 cases of CRC was 49.3%(66/134),and the exon 2 mutation rate was 42.5%(57/134)，including the 12 and 13 codon mutation rates,which were 35.1%(47/134) and 7.5%(10/134).The exon 3 mutation rate of codon 61 was 1.5%(2/134).The exon 4 mutation rate of 117/146 codons were 5.2%(7/134).The BRAF V600E mutation rate was 4.5%(6/134).The KRAS mutation rate was 54.5%(54/99) in the left colon,higher than right colon 34.3%(12/35).The difference was statistically significant (P＜0.05).The BRAF gene mutation rate was 14.3%(5/35) in the right colon，higher than left colon 1.0%(1/99).The difference was statistically significant (P＜0.05).However,there were not statistically significant differences between KRAS and BRAF gene mutations and clinicopathological features such as gender,age,nation,tumor size,differentiation degree,lymphatic metastasis and pathological stage (P＞0.05).The median survival time of CRC patients with KRAS gene mutation was 48 months(39.9%) and compared with 47 months (46.2%) of CRC patients with wild，the difference was not statistically significant（P＞0.05).The median survival time of CRC patients with BRAF gene mutation was 21 months (26.7%),and compared with 48 months (44.7%) for CRC patients with wild type,the difference was statistically significant (P＜0.05).The results of multivariate COX regression risk model showed that BRAF gene mutation was an independent risk factor for poor prognosis in CRC patients(B=1.664，OR=5.278，95%CI:1.505~18.516，P＜0.05),but gender,age,nation,tumor size,differentiation degree,tumor location,lymphatic metastasis and pathological stage were not independent risk factors for survival time of CRC patients (P＞0.05).Conlusion:The mutation rate of KRAS gene is high,while the mutation rate of BRAF gene is low in CRC tissues.Mutations in KRAS and BRAF genes are associated with tumor location.BRAF gene mutation is an independent risk factor for poor prognosis of CRC.

References:

［1］ SISGSL RL,MILLER KD,JEMAL A,et al.Cancer statistics,2017［J］.Cancer J Clin,2017,67(1):7-30.
［2］ ANTONIA R,SEPULVEDA MD,STANLEY R,et al.Molecular biomarkers for the evaluation of colorectal cancer［J］.J Mol Diagn,2017,19(2):187-225.
［3］ EDOARDO I,ANNA G,GABRIELLA C,et al.Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer［J］.TransI Med,2019,137(17):1-10.
［4］ RUI Y,WANG C,ZHOU Z,et al.KRAS mutation and prognosis of colorectal cancer:A meta-analysis［J］.Hepatogastroenterology,2015,62(137)：19-24.
［5］ SELCUKBIRICIK F，ERDAMAR S，OZKURT CU，et al.The role of KRAS and BRAF mutations as biomarkers in metastatic colorectal cancer［J］.J BUON，2013，18（1）：116-123.
［6］ MALHOTRA P，ANWAR M，NANDA N，et al.Alterations in K - ras，APC and p53-multiple genetic pathway in colorectal cancer among Indians［J］.Tumour Biol，2013，34（3）：1901-1911.
［7］高静，孙志伟，李艳艳，等.中国结直肠癌患者966例中KRAS和BRAF基因突变分析［J］.中华病理学杂志，2012,9（41）：579-583. GAO J,SUN ZW,LI YY,et al.Analysis of KRAS and BRAF gene mutations in 966 patients with colorectal cancer in China ［J］.Chin J Pathol,2012,9(41):579-583.
［8］LEA IA,JACKSON MA,LI X，et al.Genetic pathways and mutation profiles of human cancer site and exposure specific patterns ［J］.Carcinogenesis,2007,28(9):1851-1858.
［9］ 刘影，郑细闰，朱亚珍，等.252例结直肠癌组织中KRAS、NRAS、BRAF、PIK3CA的基因突变分析［J］.临床与实验病理学杂志，2016，32（8）：851-859. LIU Y,ZHENG XR,ZHU YZ，et al.Analysis of KRAS,NRAS,BRAF and PIK3CA gene mutations in 252 colorectal cancer tissues［J］.J Clin and Exp Pathol,2016,32(8):851-859.
［10］ MACEDO MP,MELO FM,LISBOA BC,et al.KRAS gene mutation in the series of unselected colorectal carcinoma patients with prognostic morphological correlations:Apyrosequencing method improved by nested PCR［J］.Exp Mol Pathol,2015,98(3):563-567.
［11］ 孙林雍,江丹，何度，等.结直肠癌组织中基因突变与临床病理及MMR蛋白表达相关性分析［J］.诊断病理学杂志，2019，26（6）：354-358. SUN LY,JIANG D,HE D,et al.Correlation analysis of gene mutations between clinicopathology and the expressiono of MMR protein in colorectal cancer tissues ［J］.Diagn J Pathol,2019，26（6）：354-358.
［12］ MARCO V,ANTONIO MB,FRANCESCO B,et al.Biomarkers in colorectal cancer:Current clinical utility and future perspectives［J］.World J Clin Cases,2018,6(15):869-881.
［13］ 谢明智，李科志，利基林,等.结直肠癌KRAS和BRAF 基因突变及其与临床病理关系［J］.广东医学，2019,40（8）:1128-1131. XIE MZ,LI KZ,LI JL,et al.KRAS and BRAF gene mutations in colorectal cancer and their relationship with clinicopathology ［J］.Guangdong Med,2019,40(8):1128-1131.
［14］ ZAHRANI A,KANDIL M,BADAR T,et al.Clinocopathological study of KRAS mutations in colorectal tumors in Arabia［J］.Tumori,2014,100(1):75-79.
［15］ 孙屏，万佳艺，吴靓骅，等.结直肠癌KRAS、NRAS、BRAF基因突变及其临床病理相关性研究［J］.中华普通外科杂志，2016,31（1）：50-54. SUN P,WAN JY,WU JH,et al.KRAS,NRAS,BRAF gene mutations and their clinicopathological correlation in colorectal cancer ［J］.Chinese Journal of General Surgery,2016,31(1):50-54.
［16］ DAEYOUN DW,JAE IL,LN KL,et al.The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients［J］.BMC Cancer，2017,17:403-415.
［17］ XI CW,QING W,JING G,et al.Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer:a retrospective observational study［J］.Chin J Cancer，2017，36:81-89.
［18］ ARNOLD D,LUEZA B,DOUILLARD JY,et al.Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials［J］.Ann of Oncol,2017，28(8):1713-1729.
［19］ 陈伊，韦常宏，宁淑芳，等.结直肠癌组织KRAS、BRAF基因突变情况及其临床意义［J］.山东医药，2017，57（16）:77-79. CHEN Y,WEI CH,NING SF,et al.KRAS and BRAF gene mutations in colorectal cancer tissues and their clinical significance ［J］.Shandong Med,2017,57(16):77-79.
［20］ LEE JH,AHN J,PARK WS,et al.Colorectal cancer prognosis is not associated with BRAF and KRAS mutations-a STROBE compliant study［J］.J Clin Med,2019,8:111-121.

Memo

Memo:
新疆维吾尔自治区自然科学基金（编号：2018D01C254）
Last Update: 1900-01-01